Federal Ministry of Health (BMG)

DIMDI is an institute within the scope of the Federal Ministry of Health (BMG). The BMG is responsible for a large number of policy areas. The work concentrates on drafting laws, ordinances and administrative regulations. The aim is to further develop the quality of the health system, to strengthen the interests of patients, to guarantee economic efficiency and to stabilise contribution rates. The BMG division also includes:

Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)

Logo: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (c) BfArM

The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is an independent federal higher authority within the portfolio of the Federal Ministry of Health. At the BfArM, roughly 1,000 employees (physicians, pharmacists, chemists, biologists, lawyers, engineers, technical assistants, administrative staff etc.) are involved in the tasks of licensing, improving the safety of medicinal products, detecting and evaluating the risks of medical devices, and monitoring the legal traffic in narcotic drugs and precursors. The most important aim of these activities is to increase the safety of medicinal products and thus that of the patients. Consequently, the BfArM makes a major contribution towards the prevention of risks to public health.

The Federal Centre for Health Education (BZgA)

Logo: Bundeszentrale für gesundheitliche Aufklärung (BzgA) (c) BzgA

The Federal Centre for Health Education aims to prevent health risks and support health-promoting lifestyles of citizens. To this end, it develops strategies for health education and prevention and implements them in nationwide campaigns and projects.

Paul-Ehrlich-Institute for Vaccines and Biomedicines, Langen

Logo: Paul-Ehrlich-Institut (PEI) (c) PEI

The Paul Ehrlich Institute, Federal Institute for Vaccines and Biomedical Drugs, makes a significant contribution to the availability and safety of effective biomedical drugs. The regulatory tasks of the institute include not only approval but also scientific advice on drug development, approval of clinical trials, experimental product testing and state batch release as well as the evaluation of drug side effects.

Robert-Koch-Institute (RKI), Berlin

Logo: Robert Koch Institut (RKI) (c) RKI

The Robert Koch Institute is the central federal institution for the detection, prevention and control of diseases, especially infectious diseases. It evaluates, analyses and researches diseases of high danger, widespread or of great public or health policy significance.

This website uses session cookies to ensure certain functionalities such as downloads or login to closed areas. In order to optimize the website, we use the analysis tool Matomo. Our Matomo installation works without tracking cookies. You will find more detailed information and the possibilities to object to the use of Matomo in our data privacy declaration.